PHASE II STUDY EVALUATING THE ACTIVITY AND TOXICITY OF A BIWEEKLY SCHEDULE OF GEMCITABINE AND PACLITAXEL IN ANTHRACYCLINE-PRETREATED BREAST CANCER

被引：0
|
作者：
Spinelli, G. P. [1 ]
Di Seri, M. [1 ]
Mezi, S. [1 ]
Oliveti, A. [1 ]
Tomao, F. [1 ]
Petricola, F. [1 ]
Rosati, S. [1 ]
Ricciardi, S. [1 ]
Coletta, D. [1 ]
Romiti, A. [1 ]
Frati, L. [1 ]
Tomao, S. [1 ]
机构：
[1] Univ Roma La Sapienza, Dept Expt Med & Pathol, Rome, Italy
来源：
ANNALS OF ONCOLOGY | 2004年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：24 / 24
页数：1
相关论文
共 50 条
  • [31] Phase II study of gemcitabine plus paclitaxel in metastatic breast cancer patients with prior anthracycline exposure
    Demiray, M
    Kurt, E
    Evrensel, T
    Kanat, O
    Arslan, M
    Saraydaroglu, O
    Ercan, K
    Gonullu, G
    Gokgoz, S
    Topal, U
    Tolunay, S
    Tasdelen, I
    Manavoglu, O
    CANCER INVESTIGATION, 2005, 23 (05) : 386 - 391
  • [32] Phase II study biweekly paclitaxel, doxorubicin and gemcitabine as first line chemotherapy for metastatic breast cancer (MBC).
    Sanchez-Rovira, P
    González, E
    Porras, I
    Jaén, A
    Medina, B
    Fernández, M
    Mohedano, N
    Lozano, A
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S52 - S52
  • [33] Biweekly gemcitabine–paclitaxel, gemcitabine–carboplatin, or gemcitabine–cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial
    Binghe Xu
    Zefei Jiang
    Sung-Bae Kim
    Shiying Yu
    Jifeng Feng
    Artur Malzyner
    Auro del Giglio
    Hyun C. Chung
    Li Jun Shen
    Daniel Lee Kay Pen
    Breast Cancer, 2011, 18 : 203 - 212
  • [34] Phase III study of gemcitabine plus docetaxel versus capecitabine plus docetaxel for anthracycline-pretreated metastatic breast cancer patients: survival results
    Chan, S.
    Romieu, G.
    Huober, J.
    Tubiana-Hulin, M.
    Schneeweiss, A.
    Lluch, A.
    Llombart, A.
    du Bois, A.
    Carrasco, E.
    Thareau, Vaury A.
    Fumoleau, P.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S68 - S68
  • [35] Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer
    Bunnell, Craig
    Vahdat, Linda
    Schwartzberg, Lee
    Gralow, Julie
    Klimovsky, Judith
    Poulart, Valerie
    Peck, Ronald
    Thomas, Eva
    CLINICAL BREAST CANCER, 2008, 8 (03) : 234 - 241
  • [36] Paclitaxel administration on days 1 and 8 every 21 days in anthracycline-pretreated metastatic breast cancer patients. A multicenter phase II trial
    M. Donadio
    E. Manzin
    A. Berruti
    A. Bottini
    G. Gorzegno
    S. Danese
    E. DeFabiani
    M.G. Sarobba
    V. Lorusso
    F. Castiglione
    G. Moro
    O. Bertetto
    C. Bumma
    L. Dogliotti
    Cancer Chemotherapy and Pharmacology, 2001, 47 : 391 - 396
  • [37] Phase II and pharmacological study of oral paclitaxel plus cyclosporine A in anthracycline pretreated metastatic breast cancer.
    Helgason, HH
    Kruijtzer, CMF
    Huitema, ADR
    Marcus, S
    Ten Bokkel-Huinink, WW
    Schot, ME
    Schornagel, JH
    Beijnen, JH
    Schellens, JHM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 41S - 41S
  • [38] Biweekly administration of gemcitabine and cisplatin chemotherapy in patients with anthracycline and taxane-pretreated metastatic breast cancer
    Tas, Faruk
    Guney, Nese
    Derin, Duygu
    Camlica, Hakan
    Aydiner, Adnan
    Topuz, Erkan
    INVESTIGATIONAL NEW DRUGS, 2008, 26 (04) : 363 - 368
  • [39] Biweekly administration of gemcitabine and cisplatin chemotherapy in patients with anthracycline and taxane-pretreated metastatic breast cancer
    Faruk Tas
    Nese Guney
    Duygu Derin
    Hakan Camlica
    Adnan Aydiner
    Erkan Topuz
    Investigational New Drugs, 2008, 26 : 363 - 368
  • [40] Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naive and anthracycline pretreated metastatic breast cancer patients
    Fabi, A
    Ferretti, G
    Papaldo, P
    Salesi, N
    Ciccarese, M
    Lorusso, V
    Carlini, P
    Carpino, A
    Mottolese, M
    Cianciulli, AM
    Giannarelli, D
    Sperduti, I
    Felici, A
    Cognetti, F
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 57 (05) : 615 - 623
12345